PMA device
Visian Implantable Collamer Lenses
STAAR Surgical Company · Lens, Intraocular, Phakic (MTA, Class III) · First FDA decision Dec 22, 2014, newest Dec 22, 2014Nearsightedness and refractive error
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
7
Naming "Visian"
MAUDE reports
3,929
Brand "Visian", since 2015
PubMed studies
197
Mentioning "Visian"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Visian Implantable Collamer Lenses
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- VISIAN IMPLANTABLE COLLAMER LENSESPMA supplement
P030016-S027 · Decided Dec 22, 2014 · 252 days after receipt · Normal 180 Day Track
Device type: Lens, intraocular, phakic (MTA) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Visian", any status and sponsor, newest update first.
Staar Surgical CompanyNot on our public-company list
NCT03499821 · 41 participants · Start Mar 20, 2018 · Primary completion Jul 9, 2019
Device: EDOF ICL · For: Presbyopia
Sites: Antwerp, Belgium; Oviedo, Spain; Almería, Spain · 6 sites in all
Staar Surgical CompanyNot on our public-company list
NCT04283149 · 327 participants · Start Jan 30, 2020 · Primary completion Apr 5, 2021
Device: EVO/EVO+ Visian ICL · For: Myopia; Myopic Astigmatism
Sites: Phoenix, Arizona; Honolulu, Hawaii; Indianapolis, Indiana · 14 sites in all
Staar Surgical CompanyNot on our public-company list
NCT04516772 · 125 participants · Start Jul 21, 2020 · Primary completion Dec 11, 2024
Device: Visian TICL · For: Myopic Astigmatism
Sites: Honolulu, Hawaii; Indianapolis, Indiana; Bowie, Maryland · 8 sites in all
4 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Visian", and for the whole product code for context.
This brand
3,929 reports: 38 malfunction, 3,891 injury, 0 death
Whole product code MTA
18,526 reports: 3,641 malfunction, 14,883 injury, 2 death
Newest reports for this brand
2023826-2026-02047 · Received Oct 30, 2026 · Event dated May 12, 2026
Device type: Phakic Toric Intraocular Lens (QCB)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Blurred Vision
2023826-2026-02051 · Received Oct 30, 2026 · Event dated Sep 30, 2026
Device type: Phakic Toric Intraocular Lens (QCB)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Visual Disturbances
2023826-2026-02052 · Received Oct 30, 2026 · Event dated Sep 30, 2026
Device type: Phakic Toric Intraocular Lens (QCB)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Visual Disturbances
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1480-2026 · Started Jan 21, 2026 · Posted by FDA Mar 2, 2026
Reason given: Toric Implantable Collamer for correction/reduction of myopia in phakic eyes with astigmatism were labeled as 12.1 mm length but are 12.6 mm length lenses, so there is the potential for excessive vault, which may cause: Significant reduction of irido-corneal angles, Significant shallowing of anterior chamber, Patient...
Cause as FDA categorized it: Process control · Device type: Phakic Toric Intraocular Lens (QCB)
Z-0464-2024 · Started Sep 29, 2023 · Posted by FDA Dec 1, 2023
Reason given: Their is a potential that intraocular implant devices may not meet specifications.
Cause as FDA categorized it: Software design (manufacturing process) · Device type: Lens, Intraocular, Phakic (MTA)
Z-0465-2024 · Started Sep 29, 2023 · Posted by FDA Dec 1, 2023
Reason given: Their is a potential that intraocular implant devices may not meet specifications.
Cause as FDA categorized it: Software design (manufacturing process) · Device type: Lens, Intraocular, Phakic (MTA)
5 more recall records with a free account
Published research
The most relevant PubMed records for "Visian"[tiab]. The summary above synthesizes these.
- EVO/EVO+ Visian Implantable Collamer Lenses for the correction of myopia and myopia with astigmatism.
Martínez-Plaza E, López-de la Rosa A, López-Miguel A, et al. · Expert Rev Med Devices · 2023Review
- Visian Collamer phakic intraocular lens in high myopic Asian eyes.
Chang JS, Meau AY · J Refract Surg · 2007
- Clinical results of Visian implantable collamer lens implantation according to various sizes and implantation angles.
Kim BK, Chung YT · Eur J Ophthalmol · 2022
- Effect of the EVO+ Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life.
Martínez-Plaza E, López-Miguel A, López-de la Rosa A, et al. · Am J Ophthalmol · 2021Research Support, Non-U.S. Gov't
- State of refractive surgery with Visian ICL posterior chamber phakic lens in Spain.
Lisa Fernández C, Alió Del Barrio J, Alvarez-Rementería Capelo L, et al. · Arch Soc Esp Oftalmol (Engl Ed) · 2023Multicenter Study
- Comparison of Implantable Collamer Lens Visian ICL V4 and ICL V4c for high myopia: A cohort study.
Tian Y, Jiang HB, Jiang J, et al. · Medicine (Baltimore) · 2017Comparative Study, Observational Study
- Two-Year Outcomes of Visian Implantable Collamer Lens with a Central Hole for Correcting High Myopia.
Yan Z, Miao H, Zhao F, et al. · J Ophthalmol · 2018
- Episodic Angle Closure after Visianࡊ Implantable Collamer Lens Implantation in a Patient Using Adderall®.
Moshirfar M, Moin KA, Jaafar M, et al. · Case Rep Ophthalmol · 2024Case Reports
- Incidence of implantable Collamer lens-induced cataract.
Gimbel HV, LeClair BM, Jabo B, et al. · Can J Ophthalmol · 2018Observational Study
- Comparison of the Visian ICL and Verisyse phakic intraocular lenses for myopia from 6.00 to 20.00 diopters.
Boxer Wachler BS, Scruggs RT, Yuen LH, et al. · J Refract Surg · 2009Comparative Study
- Visian® ICLV4cࡊ and Artiflex®: Comparative Analysis with the HD AnalyserTM and Integration with Subjective Performance and Anatomical Parameters.
Baptista PM, Monteiro S, Abreu AC, et al. · Clin Ophthalmol · 2020
- Visian toric ICL implantation after intracorneal ring segments implantation and corneal collagen crosslinking in keratoconus.
Dirani A, Fadlallah A, Khoueir Z, et al. · Eur J Ophthalmol · 2014
Other devices of this type
Also filed under product code MTA.
- Visian Icl (Implantable Collamer Lens)STAAR Surgical Company · PMA 2025
- EVO Visian Implantable Collamer Lens for Myopia (VICMO)STAAR Surgical Company · PMA 2025
- EVO/EVO+ VISIAN® Implantable Collamer® LensesSTAAR Surgical Company · PMA 2022
- Visian Toric ICL (Implantable Collamer Lens)STAAR Surgical Company · PMA 2019
- ARTISAN/Verisyse Myopia Phakic Intraocular Lens (IOL)Ophtec BV · PMA 2018
- Staar Surgical Implantable Collamer Lens (Vision Icl)STAAR Surgical Company · PMA 2017
- Artisan MyopiaOphtec BV · PMA 2024
- EVO/EVO+VISIAN Implantable Collamer LensSTAAR Surgical Company · PMA 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.